We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

QIAGEN Launches New CE-Marked Respiratory Four-Plex Panel That Differentiates Between Flu, RSV and SARS-CoV-2

By LabMedica International staff writers
Posted on 04 Nov 2021
Image: QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 Test (Photo courtesy of QIAGEN N.V.)
Image: QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 Test (Photo courtesy of QIAGEN N.V.)

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly identify whether patients have common seasonal respiratory infections or SARS-CoV-2.

QIAGEN’s new Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test is a powerful diagnostic tool in the COVID-19 pandemic, especially in influenza like illness (ILI) or “flu” seasons. It leverages the easy-to-use QIAstat-Dx modular cartridge-based system to deliver fast results that require no additional sample preparation. The polymerase chain reaction (RT-PCR) multiplex test detects and differentiates between influenza A and B, respiratory syncytial virus (RSV) and SARS-CoV-2 infections in about an hour - a vital capability in the fight against the COVID-19 pandemic. The viruses produce similar respiratory symptoms, making it challenging to clinicians to diagnose exactly which one a patient is suffering from to make the right treatment decisions.

“This new test expands the capabilities of our QIAstat-Dx system with a much-needed COVID-19 application that differentiates between respiratory infections quickly without lab infrastructure,” said Jean-Pascal Viola, Senior Vice President, Head of the Molecular Diagnostics Business Area and Corporate Business Development at QIAGEN. “With flu season and COVID-19 case numbers still high, this test provides a crucial tool that can be used close to patients and in decentralized environments like ICUs, emergency rooms and satellite labs. By adding this new test to our growing QIAstat-Dx testing menu, we are taking another step to increase the platform’s value for customers beyond the pandemic.”

Related Links:
QIAGEN N.V.

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Portable Electronic Pipette
Mini 96
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
New
Gold Member
Hybrid Pipette
SWITCH

Channels

Molecular Diagnostics

view channel
Image: The genomic test measures eight gene activities in a melanoma tumor and combines this data with patient factors like age and tumor thickness (Photo courtesy of 123RF)

Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients

Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
GLOBE SCIENTIFIC, LLC